Engineered vesicle carriers for intracellular peptide delivery
This technology engineers milk-derived exosomes — tiny natural vesicles found in milk — to serve as drug delivery vehicles. The key innovation is a chemical loading method: therapeutic peptides are temporarily modified with a protective coating that masks their negative charge, allowing them to slip inside the exosomes. Once inside, enzymes naturally present in the milk exosomes strip off the protective coating, trapping the drug cargo within. The result is a loaded, stable exosome formulation ready for pharmaceutical use, with potential applications in neurological, cardiovascular, skin, and eye diseases based on the CPC codes.
What you could build
A drug delivery platform using bovine milk-derived exosomes as natural, orally or topically administrable carriers for peptide therapeutics — most immediately attractive to biotech and pharma companies developing peptide drugs for conditions like retinal disease, cardiac arrhythmia, or CNS disorders where current delivery methods are inadequate.
Who in Virginia should care
Biotech and pharmaceutical companies in the Northern Virginia/DC corridor, or agricultural and dairy-adjacent bioprocessing firms in rural Virginia, could find this relevant for licensing or sponsored research.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Robert G. GOURDIE, L. Jane JOURDAN, Eda ROGERS
- Filed
- Patent pending — filed February 14, 2025
- Status
- Application
- Publication number
- US20250221936A1
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.